Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in
serum and liver tissue of patients undergoing liver resection due to primary or secondary
tumor of the liver.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Saarland
Collaborator:
Bayer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination